New and Emerging Treatments for Rosacea
- 760 Downloads
Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans. The multifactorial pathophysiology of rosacea is not fully understood. Several new treatment options were recently US Food and Drug Administration approved or are in clinical trials. This paper reviews new treatment options including ivermectin, brimonidine, the new foam formulation of azelaic acid, and oxymetazoline. The potential role in therapy, patient selection, and adverse effects of these agents are discussed.
KeywordsIvermectin Skin Irritation Rosacea Azelaic Acid Brimonidine
Compliance with Ethical Standards
No funding was received for the preparation of this manuscript. Zoe Draelos has received payments for research from Bayer and Galderma.
Conflict of interest
Lauren Gold has no conflicts of interest.
- 1.Baldwin H. Psychosocial implications of rosacea. Dermatologist. 2012;Suppl.:2–4.Google Scholar
- 3.Gupta MA, Gupta AK, Chen SJ, Johnson AM. Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey: Outpatient Department data collected by the U.S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol. 2005;153(6):1176–81.CrossRefPubMedGoogle Scholar
- 7.Del Rosso JQ, Gallo RL, Kircik L, et al. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. Drugs Dermatol. 2012;11:694–700.Google Scholar
- 13.Merck & Co. Inc. Stromectal (ivermectin) tablets. 2010. Available from: https://www.merck.com/product/usa/pi_circulars/s/stromectol/stromectol_pi.pdf. Accessed 21 June 2015.
- 14.Khan I, Yasmin R. Ivermectin in the treatment of scabies. J Pakistan Assoc Dermatol. 2007;17:78–83.Google Scholar
- 19.Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J. Long-term safety of ivermectin 1 % cream vs azelaic acid 15 % gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13:1380–6.Google Scholar
- 22.Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650–6.PubMedGoogle Scholar
- 23.Moore A, Kempers S, Murakawa G, Weiss J, Tauscher A, Swinyer L, Liu H, Leoni M. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5 for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13(1):56–61.PubMedGoogle Scholar
- 24.Tanghetti EA, Jackson JM, Belasco KT, Friedrichs A, Hougier F, Johnson SM, Kerdel FA, Palceski D, Hong HC, Hinek A, Cadena MJ. J Optimizing the use of topical brimonidine in rosacea management: panel recommendations. Drugs Dermatol. 2015;14(1):33–40.Google Scholar
- 25.ClinicalTrials.gov. Safety and efficacy of AGN-199201 in patients with persistent erythema associated with rosacea. Available at: https://clinicaltrials.gov/ct2/show/NCT02132117?term=allergan+rosacea&rank=1. Accessed 21 June 2015.
- 26.Galderma. Soolantra package insert, 2014. Available at: http://www.galdermausa.com/pi/soolantrapi.pdf. Accessed 8 Sept 2015.
- 27.Bayer. Finacea foam, 15 % package insert, 2015. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Finacea_Foam_PI.pdf. Accessed 8 Sept 2015.